Skip to main content
Erschienen in:

01.09.2011 | Leitthema

Therapie des Mantelzelllymphoms

verfasst von: Prof. Dr. M. Dreyling

Erschienen in: Die Onkologie | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Mantelzelllymphom ist durch eine charakteristische Cyclin-D1-Überexpression und einen relativ rasch rezidivierenden Verlauf gekennzeichnet. Histologie und Klinik können jedoch stark variieren, sodass zur individuellen Risikoabschätzung histologische, klinische und biologische Faktoren herangezogen werden. Für die große Mehrheit der Fälle sollte jedoch nach Diagnosestellung rasch eine entsprechende Therapie eingeleitet werden. Bei jüngeren Patienten wiesen mehrere Studien den Vorteil dosisintensivierter Ansätze mit einer autologen Stammzelltransplantation nach, eine aktuelle randomisierte Phase-III-Studie belegt den zusätzlichen Vorteil eines cytarabinhaltigen Regimes. Bei älteren Patienten erzielt eine kombinierte Immunchemotherapie initial hohe Ansprechraten, zur Erzielung lang anhaltender Remissionen sind jedoch weitere Konsolidierungsstrategien notwendig. In einer kürzlich präsentierten Studie des Europäischen MCL Netzwerks führte eine Rituximaberhaltung zu einer mittleren Remissionsdauer von ca. 6 Jahren. Aktuelle Studienkonzepte prüfen Kombinationen mit molekular gezielten Substanzen (Proteasominhibitoren, IMIDs und mTOR-Inhibitoren).
Literatur
1.
Zurück zum Zitat Martin P, Chadburn A, Christos P et al (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27(8):1209–1213PubMedCrossRef Martin P, Chadburn A, Christos P et al (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27(8):1209–1213PubMedCrossRef
2.
Zurück zum Zitat Hoster E, Hasford J, Hermine O et al (2009) Confirmation of the mantle cell lymphoma international prognostic index (MIPI) in an independent prospective patient cohort. Blood (ASH Annual Meeting Abstracts) 114(22):#138 Hoster E, Hasford J, Hermine O et al (2009) Confirmation of the mantle cell lymphoma international prognostic index (MIPI) in an independent prospective patient cohort. Blood (ASH Annual Meeting Abstracts) 114(22):#138
3.
Zurück zum Zitat Determann O, Hoster E, Ott G et al (2008) Ki-67 predicts outcome in advanced stage mantle cell lymphoma patients treated with anti-CD20 immunochemo-therapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111(4):2385–2387PubMedCrossRef Determann O, Hoster E, Ott G et al (2008) Ki-67 predicts outcome in advanced stage mantle cell lymphoma patients treated with anti-CD20 immunochemo-therapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111(4):2385–2387PubMedCrossRef
4.
Zurück zum Zitat Nickenig C, Dreyling M, Hoster E et al (2006) Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 107(5):1014–1022PubMedCrossRef Nickenig C, Dreyling M, Hoster E et al (2006) Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 107(5):1014–1022PubMedCrossRef
5.
Zurück zum Zitat Cohen BJ et al (2001) Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 42(5):1015–1022PubMedCrossRef Cohen BJ et al (2001) Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 42(5):1015–1022PubMedCrossRef
6.
Zurück zum Zitat Ghielmini M, Schmitz SF, Cogliatti S et al (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23(4):705–711PubMedCrossRef Ghielmini M, Schmitz SF, Cogliatti S et al (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23(4):705–711PubMedCrossRef
7.
Zurück zum Zitat Hoster E, Unterhalt M, Wörmann B et al (2008) The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial. ASH Annual Meeting Abstracts 112(11):#3049 Hoster E, Unterhalt M, Wörmann B et al (2008) The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial. ASH Annual Meeting Abstracts 112(11):#3049
8.
Zurück zum Zitat Schulz H, Bohlius J, Skoetz N et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99(9):706–714PubMedCrossRef Schulz H, Bohlius J, Skoetz N et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99(9):706–714PubMedCrossRef
9.
Zurück zum Zitat Rummel MJ, Niederle N, Maschmeyer G et al (2009) Bendamustin plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL. ASH #405 Annual Meeting Abstracts, 114(12) Rummel MJ, Niederle N, Maschmeyer G et al (2009) Bendamustin plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL. ASH #405 Annual Meeting Abstracts, 114(12)
10.
Zurück zum Zitat Kluin-Nelemans JC, Hoster E, Vehling-Kaiser U et al (2011) Rituximab maintenance significantly prolongs duration of remission in elderly patients with mantle cell lymphoma. First results of a randomized trial of the European MCL Network. EHA Kluin-Nelemans JC, Hoster E, Vehling-Kaiser U et al (2011) Rituximab maintenance significantly prolongs duration of remission in elderly patients with mantle cell lymphoma. First results of a randomized trial of the European MCL Network. EHA
11.
Zurück zum Zitat Dreyling M, Hiddemann W (2009) Therapy of mantle cell lymphoma, in american society of hematology education program book. Hematology 542–554 Dreyling M, Hiddemann W (2009) Therapy of mantle cell lymphoma, in american society of hematology education program book. Hematology 542–554
12.
Zurück zum Zitat Romaguera JE, Fayad LE, Feng L et al (2010) Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyper-CVAD alternating with rituximab-high dose methotrexate/cyrarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150:200–208PubMed Romaguera JE, Fayad LE, Feng L et al (2010) Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyper-CVAD alternating with rituximab-high dose methotrexate/cyrarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150:200–208PubMed
13.
Zurück zum Zitat Geisler CH et al (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687–2693PubMedCrossRef Geisler CH et al (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687–2693PubMedCrossRef
14.
Zurück zum Zitat Hermine O, Hoster E, Walewski J et al (2010) Alternating courses of 3 × CHOP and 3 × DHAP plus rituximab followed by a high dose AraC containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 course CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of die MCL Younger Trial of the European mantle cell lymphoma network (MCL net). ASH 2010 Annual Meeting Abstracts 116, Abstract 110 Hermine O, Hoster E, Walewski J et al (2010) Alternating courses of 3 × CHOP and 3 × DHAP plus rituximab followed by a high dose AraC containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 course CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of die MCL Younger Trial of the European mantle cell lymphoma network (MCL net). ASH 2010 Annual Meeting Abstracts 116, Abstract 110
15.
Zurück zum Zitat Wang M, Oki Y, Pro B et al (2009) Phase II study of yttrium-90 (90Y)-Ibritumomab Tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:5213–5218PubMedCrossRef Wang M, Oki Y, Pro B et al (2009) Phase II study of yttrium-90 (90Y)-Ibritumomab Tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:5213–5218PubMedCrossRef
16.
Zurück zum Zitat Hoster E, Metzner B, Forstpointner R et al (2009) Autologous stem cell transplantation and addition of rituximab independently prolong response Duration in Advanced Stage Mantle Cell Lymphoma. ASH Annual Meeting Abstracts 114(22):#880 Hoster E, Metzner B, Forstpointner R et al (2009) Autologous stem cell transplantation and addition of rituximab independently prolong response Duration in Advanced Stage Mantle Cell Lymphoma. ASH Annual Meeting Abstracts 114(22):#880
17.
Zurück zum Zitat Pott C, Hoster E, Delfau-Larue MH (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115:3215–3223PubMedCrossRef Pott C, Hoster E, Delfau-Larue MH (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115:3215–3223PubMedCrossRef
18.
Zurück zum Zitat Forstpointner R, Unterhalt M, Dreyling M et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108(13):4003–4008PubMedCrossRef Forstpointner R, Unterhalt M, Dreyling M et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108(13):4003–4008PubMedCrossRef
19.
Zurück zum Zitat Kluin-Nelemans JC, Hoster E, Vehling-Kaiser U et al (2011) Rituximab maintenance significantly prolongs duration of remission in elderly patients with mantle cell lymphoma. First results of a randomized trial of the European MCL Network. EHA Kluin-Nelemans JC, Hoster E, Vehling-Kaiser U et al (2011) Rituximab maintenance significantly prolongs duration of remission in elderly patients with mantle cell lymphoma. First results of a randomized trial of the European MCL Network. EHA
20.
Zurück zum Zitat Goy A et al (2009) Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20(3):520–525PubMedCrossRef Goy A et al (2009) Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20(3):520–525PubMedCrossRef
21.
Zurück zum Zitat Weigert O et al (2009) A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study. Leuk Lymphoma 50(5):716–722PubMedCrossRef Weigert O et al (2009) A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study. Leuk Lymphoma 50(5):716–722PubMedCrossRef
22.
Zurück zum Zitat Ruan J, Martin P, Furman RR et al (2011) Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29(6):690–697PubMedCrossRef Ruan J, Martin P, Furman RR et al (2011) Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29(6):690–697PubMedCrossRef
23.
Zurück zum Zitat Friedberg JW, Vose JM, Kelly JL et al (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117(10):2807–2812PubMedCrossRef Friedberg JW, Vose JM, Kelly JL et al (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117(10):2807–2812PubMedCrossRef
24.
Zurück zum Zitat Witzig TE, Vose JM, Zinzani PL et al (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 22:1622–1627PubMedCrossRef Witzig TE, Vose JM, Zinzani PL et al (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 22:1622–1627PubMedCrossRef
25.
Zurück zum Zitat Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822–3829PubMedCrossRef Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822–3829PubMedCrossRef
26.
Zurück zum Zitat Dreyling M, Kluin-Nelemans H, Beà S et al (2011) Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma – report of the 10th annual conference of the EUROPEAN MANTLE CELL NETWORK. Leuk Lymphoma, Epub Dreyling M, Kluin-Nelemans H, Beà S et al (2011) Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma – report of the 10th annual conference of the EUROPEAN MANTLE CELL NETWORK. Leuk Lymphoma, Epub
27.
Zurück zum Zitat Kahl B, Byrd JC, Flinn I et al (2010) Clinical safety and activity In a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-Kinase P110δ in patients with relapsed or refractory non-Hodgkin lymphoma. ASH Annual Meeting Abstracts116, Abstract 1777 Kahl B, Byrd JC, Flinn I et al (2010) Clinical safety and activity In a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-Kinase P110δ in patients with relapsed or refractory non-Hodgkin lymphoma. ASH Annual Meeting Abstracts116, Abstract 1777
28.
Zurück zum Zitat Fowler N, Sharman JP, Smith SM et al (2010) The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. ASH Annual Meeting Abstracts, Abstract 964 Fowler N, Sharman JP, Smith SM et al (2010) The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. ASH Annual Meeting Abstracts, Abstract 964
29.
Zurück zum Zitat Herold M, Haas A, Doerhen et al (2008) Immunchemotherapy (RMCP) in advanced stage mantle cell lymphoma is not superior to chemotherapy (MCP) alone. 50 month update of the OSHO phase III trial (OSHO #39). Ann Oncol 19:#012 Herold M, Haas A, Doerhen et al (2008) Immunchemotherapy (RMCP) in advanced stage mantle cell lymphoma is not superior to chemotherapy (MCP) alone. 50 month update of the OSHO phase III trial (OSHO #39). Ann Oncol 19:#012
30.
Zurück zum Zitat Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984–1992PubMedCrossRef Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984–1992PubMedCrossRef
Metadaten
Titel
Therapie des Mantelzelllymphoms
verfasst von
Prof. Dr. M. Dreyling
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 9/2011
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-011-2129-2

Weitere Artikel der Ausgabe 9/2011

Die Onkologie 9/2011 Zur Ausgabe

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.